Ampyra

The FDA approved Ampyra (dalfampridine) to improve walking in multiple sclerosis. In two phase 3 trials, 34.8 and 42.9 percent of patients taking the 10mg tablet twice daily walked faster, against 8.3 and 9.3 percent on placebo, though the company says the size of the difference was not established.